我吃西红柿,欢乐颂第三季

Drugverse

藥宇宙（Drugverse）的創(chuàng)始人郭均相先生

Mr. Guo Junxiang, Founder of Drugverse

郭均相先生：1979年12月出生，中國(guó)國(guó)籍，無(wú)境外永久居留權(quán)，云南師范大學(xué)碩士研究生，醫(yī)藥領(lǐng)域超20年工作經(jīng)歷，先后在康恩貝#600572·SH、君業(yè)藥業(yè)（激素CDMO）、DoePharma（CDMO研發(fā)公司）等公司擔(dān)任Director、VP、President。2020年開(kāi)始出任上市藥企寧波美諾華藥業(yè)#603538·SH、東陽(yáng)光長(zhǎng)江藥業(yè)#01558·HK戰(zhàn)略顧問(wèn)，因?yàn)樵谑召?gòu)入股原料藥、醫(yī)藥中間體及CDMO/CRO企業(yè)的市值管理和CXO業(yè)務(wù)（CMO&CDMO為主）、項(xiàng)目Licence in&out上的前瞻性布局，為中國(guó)藥企在創(chuàng)新藥/搶仿領(lǐng)域上的產(chǎn)品管線(xiàn)布局指明方向、破局內(nèi)卷上建樹(shù)頗豐，2023年初至今，被中國(guó)化工企業(yè)管理協(xié)會(huì)提名為副會(huì)長(zhǎng)，并榮獲中國(guó)醫(yī)藥行業(yè)著名戰(zhàn)略家美譽(yù)。

Mr. Guo Junxiang is a Chinese national born in December 1979, with no permanent residence abroad. He holds a master’s degree from Yunnan Normal University and has over 20 years of experience in the pharmaceutical industry. He has served as a director, vice president, and president in various pharmaceutical companies, such as Zhejiang Conba Pharmaceutical Co., Ltd. (#600572?SH) 、Zhejiang Xianju JUNYE Pharmaceutical Co., Ltd. (steroid CDMO) and DoePharma (CDMO). Since 2020, He has served as a senior business strategy consultant for two Chinese listed pharmaceutical companies: Ningbo Menovo Pharmaceutical Co., Ltd. (#603538?SH) and YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (#01558?HK). Mr. Guo has played a key role in guiding Chinese pharmaceutical companies on their prospective product pipeline planning (both innovative and generic medicines) in terms of stake purchasing API & pharmaceutical intermediate enterprises, managing the market value of CDMO/CRO, developing CXO (mainly CMO&CDMO) business, and conducting In-licensing/Out-licensing. Due to his fruitful achievements in these fields, Mr. Guo was nominated as the vice chairman of the China Chemical Enterprise Management Association in early 2023, and earned the reputation as a renowned strategist in Chinese pharmaceutical industry.

2023年7月14日，由Drugverse協(xié)辦的CIC2023中國(guó)化學(xué)藥物產(chǎn)業(yè)鏈發(fā)展峰會(huì)（CHINA CHEMICAL DRUG INDUSTRIAL DEVELOPMENT CONFERENCE）取得圓滿(mǎn)成功！

The CIC2013 China Chemical Drug Industrial Development Summit, co-organized by Drugverse, was successfully held on July 14, 2023. The summit brought together experts, scholars, and industry leaders from the related fields to discuss the latest trends, challenges and opportunities in chemical drug development. The summit also showcased the innovative solutions and products offered by Drugverse, a platform that aims to help pharmaceutical researchers in their drug development process. The summit was a great opportunity for networking, learning, and collaboration among the participants.

中國(guó)科學(xué)院院士、中國(guó)科學(xué)院上海有機(jī)化學(xué)研究所研究員馬大為參加峰會(huì)并為大會(huì)開(kāi)幕致辭，發(fā)表關(guān)于“小分子創(chuàng)新藥物發(fā)展的思考”的主旨演講.

Ma Dawei, an academician of Chinese Academy of Sciences and a researcher at the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, attended the summit and gave an opening speech. He also delivered a keynote speech on “Thoughts on the Development of Innovative Small Molecule Drugs”, in which he shared his insights and perspectives on the current status and future trends of small molecule drug research.

健艾仕（杭州）生物制藥公司董事長(zhǎng)傅新元，進(jìn)行“化學(xué)藥靶點(diǎn)選擇：以JAK- STAT 為例”的精彩分享。

Fu Xinyuan, the Chairman of the Board of GenEros (Hangzhou) Biopharma Ltd., delivered an insightful presentation on “Chemical Drug Target Selection: Using JAK-STAT as a Case Study”.

峰會(huì)就“新時(shí)代小分子創(chuàng)新藥”設(shè)置圓桌討論環(huán)節(jié)。如何評(píng)價(jià)一項(xiàng)創(chuàng)新藥研發(fā)項(xiàng)目的商業(yè)潛力和投資價(jià)值？小分子創(chuàng)新藥的研發(fā)是否能滿(mǎn)足未來(lái)醫(yī)學(xué)需求？如何加強(qiáng)中國(guó)創(chuàng)新藥研發(fā)人才培養(yǎng)和引進(jìn)，提高我國(guó)在全球創(chuàng)新藥領(lǐng)域的競(jìng)爭(zhēng)力？小分子創(chuàng)新研發(fā)和新技術(shù)的融合如何推動(dòng)醫(yī)療創(chuàng)新？圍繞這些問(wèn)題，郎盛投資集團(tuán)合伙人李佳、維亞生物首席創(chuàng)新官戴晗、燁輝醫(yī)藥科技（上海）有限公司CEO華燁、上海宇道生物技術(shù)有限公司聯(lián)合創(chuàng)始人郁征天，分別作為主持嘉賓，與相關(guān)企業(yè)代表進(jìn)行互動(dòng)交流。

The summit featured a roundtable discussion session on “Innovative Small Molecule Drugs in the New Era”. The session addressed the following questions: How can one assess the commercial potential and investment value of an innovative drug discovery project? How can the R&D of innovative small molecule drugs meet the future medical needs? How can China enhance its talent training and recruitment in the field of innovative drug R&D and improve its global competitiveness? How can the integration of small molecule innovation R&D and new technologies foster medical technology innovation? These discussion sections were hosted by Li Jia, a partner of Lang Sheng Investment Group Co., Ltd.、 Dai Han, the chief innovation officer of Viva Biotech、Hua Ye, the CEO of BioNova Pharmaceuticals (Shanghai) Ltd., and Yu Zhengtian, the co-founder of Shanghai Nutshell Biotech Co., Ltd., respectively. The hosts engaged the participants in a lively discussion on these topics and shared their insights and experiences.

目前，Drugverse的商標(biāo)持有者為大也醫(yī)藥信息咨詢(xún)(杭州)有限公司

Drugverse is a trademark owned by Daye Pharmaceutical Information Consulting (Hangzhou) Co., Ltd.

Drugverse創(chuàng)始團(tuán)隊(duì)及專(zhuān)家顧問(wèn)團(tuán)成員具備15-35年國(guó)企、民企資深產(chǎn)業(yè)領(lǐng)域經(jīng)驗(yàn)以及廣泛的國(guó)內(nèi)外人才、基金、項(xiàng)目、資源儲(chǔ)備。公司目前主要從事醫(yī)藥行業(yè)企業(yè)信息咨詢(xún)、戰(zhàn)略管理、成果轉(zhuǎn)化、創(chuàng)業(yè)輔導(dǎo)陪跑、投融資FA、政府招商引資等服務(wù)。

The founders and expert advisors of Drugverse have extensive industrial experience ranging from 15 to 35 years in both state-owned and private enterprises. They also have a rich network of domestic and foreign talents, funds, projects and resources. The company provides various services for the pharmaceutical industry, such as enterprise consulting、strategic management、 research commercialization、 entrepreneurial counseling、investment and financing FA、government investment promotion, etc.

微信公眾號(hào)請(qǐng)搜索：Drugverse

To follow us on WeChat, please search for: Drugverse

時(shí)事通訊